Related ArticlesA Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer. Anticancer Res. 2019 Jul;39(7):3295-3301 Authors: Stravodimou A, Voutsadakis IA Abstract The development of effective human epidermal growth factor receptor 2 (HER2)-targeted therapies has been heralded as a significant milestone in breast cancer treatment, resulting in improvement of the outcome...
Related ArticlesThe volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer. J Transl Med. 2019 Jul 02;17(1):182 Authors: You C, Li J, Zhi W, Chen Y, Yang W, Gu Y, Peng W Abstract BACKGROUND: To evaluate the imaging biomarkers of human epidermal growth factor receptor 2 (HER2) positive breast cancer in comparison to other molecular subtypes...
Related ArticlesThe d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers? Cancers (Basel). 2019 Jun 28;11(7): Authors: Castagnoli L, Ladomery M, Tagliabue E, Pupa SM Abstract Human epidermal growth factor receptor 2 (ERBB2 or HER2) amplification/overexpression is associated with a particularly aggressive molecular subtype of breast cancer (BC), characterized by a poor prognosis, increased metastatic potential, and disease recurrence. As only...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.